Table 3.

Characteristics of study cohort 2 and baseline statistics of CSF measurements

Cohort 2
	PET− (n = 21)	PET+ (n = 17)	p-value PET− - PET+#
Age	66.86 ± 10.95	68.29 ± 11.20	0.6928*
Gender			0.7442$
Women	9 (42.9%)	6 (35.3%)
Men	12 (57.1%)	11 (64.7%)
CSF GPNMB [pg/ml]	8074 ± 3358	8620 ± 3577	0.6845#
APOE genotype
ε2/ε2	–	–
ε2/ε3	2	–
ε2/ε4	1	1
ε3/ε3	13	7
ε3/ε4	4	8
ε4/ε4	1	1
≥ 1 APOE ε4 allele, n (%)	6 (28.6%)	10 (58.8%)	0.0990$
CSF p-Tau [pg/ml]	52.52 ± 26.59	69.76 ± 27.39	0.0367#
CSF t-Tau [pg/ml]	362.3 ± 258.4	578.0 ± 339.1	0.0225#
CSF Aβ38 [pg/ml]	2848 ± 946.1	2509 ± 734.8	0.2810#
CSF Aβ40 [pg/ml]	9294 ± 2851	8343 ± 2575	0.2929*
vCSF Aβ42 [pg/ml]	796.5 ± 336.9	441.2 ± 157.3	0.0002#
CSF Aβ ratio 42/40	0.08529 ± 0.01939	0.05433 ± 0.01949	<  0.0001#

*Unpaired t-test, ^#Mann-Whitney, or ^$Fisher’s exact test for differences between the diagnostic groups